← Eichor
Study identifier: NCT07558564 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of Platelet-Rich Plasma (PRP) Treatment in Tendinopathies

Condition: Patellar Tendinopathy · Achilles Tendinopathy (AT) · Epicondylitis, Lateral  ·  Sponsor: ReSport Clinic

PhaseN/A
Planned participants2000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This multicenter, prospective, observational study, based on real-world evidence (RWE), aims to evaluate the efficacy and safety of Platelet-Rich Plasma (PRP) treatment across four types of tendinopathies: patellar, Achilles, epicondylar, and plantar fasciosis. Data collection and analysis will be conducted using the BioSmartData® platform, including hematology analyzers for PRP characterization, clinical variables, treatment protocols, and longitudinal assessment of therapeutic response.

This description comes directly from the study's public registry record.

Talk to the study team

Resport Clinic, MD PhD  ·  +34 93 2778709  ·  abat@resportclinic.com

Always discuss trial participation with your own doctor first.

Locations (5)

Instituto Médico ArriazaA Coruña, SpainRecruiting
Instituto CugatBarcelona, SpainRecruiting
ReSport ClinicBarcelona, SpainRecruiting
Ripoll y dePrado Medical GroupMadrid, SpainRecruiting
Hospital MIKSVitoria-Gasteiz, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07558564